全文获取类型
收费全文 | 1824篇 |
免费 | 119篇 |
国内免费 | 51篇 |
专业分类
1994篇 |
出版年
2024年 | 4篇 |
2023年 | 39篇 |
2022年 | 53篇 |
2021年 | 73篇 |
2020年 | 72篇 |
2019年 | 61篇 |
2018年 | 80篇 |
2017年 | 36篇 |
2016年 | 35篇 |
2015年 | 60篇 |
2014年 | 144篇 |
2013年 | 124篇 |
2012年 | 99篇 |
2011年 | 101篇 |
2010年 | 77篇 |
2009年 | 88篇 |
2008年 | 86篇 |
2007年 | 96篇 |
2006年 | 77篇 |
2005年 | 65篇 |
2004年 | 57篇 |
2003年 | 59篇 |
2002年 | 52篇 |
2001年 | 28篇 |
2000年 | 31篇 |
1999年 | 19篇 |
1998年 | 16篇 |
1997年 | 18篇 |
1996年 | 17篇 |
1995年 | 13篇 |
1994年 | 19篇 |
1993年 | 20篇 |
1992年 | 16篇 |
1991年 | 15篇 |
1990年 | 9篇 |
1989年 | 11篇 |
1988年 | 8篇 |
1987年 | 8篇 |
1986年 | 9篇 |
1985年 | 11篇 |
1984年 | 15篇 |
1983年 | 7篇 |
1982年 | 8篇 |
1981年 | 5篇 |
1980年 | 12篇 |
1979年 | 6篇 |
1978年 | 8篇 |
1977年 | 11篇 |
1976年 | 4篇 |
1975年 | 4篇 |
排序方式: 共有1994条查询结果,搜索用时 0 毫秒
21.
22.
Expression of cell type-specific markers during pancreatic development in the mouse: implications for pancreatic cell lineages 总被引:2,自引:0,他引:2
Summary The islet cells of the mammalian pancreas are comprised of four different endocrine cell types, each containing a specific hormone. Islet cells also contain two enzymes of the catecholamine biosynthetic pathway: tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC). The cell lineage relationships of these different cell types have not been examined and it is not known whether, during development, they originate from the same or from different precursor populations. In this study we used immunocytochemical procedures to determine whether developing pancreatic cells express markers common to endocrine and exocrine cell types. We found that acinar cell precursors express AADC prior to the appearance of an exocrine marker and that the expression of AADC in acinar cells persists throughout embryogenesis to the first month of postnatal life. At this time, acinar cells do not contain AADC. We also found that exocrine cells containing AADC never express other islet-cell markers. These findings suggest that while acinar and islet cells both arise from precursor cells containing AADC, these progenitor cells do not express a combined endocrine-exocrine phenotype. 相似文献
23.
Lydia N. Raines Matthew M. Hsieh Tina Nassehi Claire M. Drysdale John F. Tisdale Naoya Uchida 《Cytotherapy》2019,21(12):1206-1215
Background aimsAllogeneic hematopoietic stem cell transplantation is curative for sickle cell disease, and the use of matched related donors, non-myeloablative conditioning and sirolimus immunosuppression results in stable mixed chimerism without graft-versus-host disease (GVHD). However, the time to terminate sirolimus while maintaining mixed chimerism is unclear.MethodsIn this study, we developed a two-way mixed lymphocyte reaction (MLR) to evaluate ex vivo immunoreaction in mixed chimeric patients.ResultsIn co-culture of peripheral blood mononuclear cells (PBMCs) from two healthy controls (without irradiation), we detected proliferation at various ratios of PBMC mixtures (1:9 to 9:1) as well as various concentrations of sirolimus, suggesting that two-way MLR is applicable to patients (having >10% chimerism) undergoing sirolimus treatment. In two-way MLR using PBMCs (including donor and recipient cells) from mixed chimeric patients (n = 28), greater ex vivo proliferation was observed <6 months compared with >6 months post-transplant and healthy control PBMC monoculture. Robust ex vivo proliferation was observed in a patient with acute GVHD, and persistent ex vivo proliferation (until 2 years) was observed in a patient with decreasing donor chimerism.ConclusionsIn summary, we demonstrated that in two-way MLR, ex vivo immunoreaction decreases to low levels ~6 months post-transplant. These findings suggest a rationale to continue immunosuppression for 6 months. 相似文献
24.
聚集在人体肠道的菌群对维持机体正常的生理功能具有重要作用,肠道菌群的失调会导致复发性艰难梭菌感染及炎症性肠病等疾病。粪菌移植是将健康供者肠道内的功能菌群转移到患病个体的肠道内,重建患者的肠道微生态环境,从而达到治疗的目的。研究发现,粪菌移植在治疗复发性艰难梭菌感染方面表现出较高的治愈率,同时对炎症性肠病有积极的疗效。益生菌是一类能发挥健康作用的活性微生物,当机体摄入足够数量的益生菌,益生菌能在宿主肠道内定植,可以恢复并维持宿主肠道菌群的平衡。益生菌可作为预防复发性艰难梭菌感染的辅助治疗,同时在缓解炎症性肠病方面也有较好的效果。 相似文献
25.
Getting the right stuff: controlling neural stem cell state and fate in vivo and in vitro with biomaterials 总被引:1,自引:0,他引:1
Stem cell therapy holds great promises in medical treatment by, e.g., replacing lost cells, re-constitute healthy cell populations and also in the use of stem cells as vehicles for factor and gene delivery. Embryonic stem cells have rightfully attracted a large interest due to their proven capacity of differentiating into any cell type in the embryo in vivo. Tissue-specific stem ceils are however already in use in medical practice, and recently the first systematic medical trials involving human neural stem cell (NSC) therapy have been launched. There are yet many obstacles to overcome and procedures to improve. To ensure progress in the medical use of stem cells increased basic knowledge of the molecular mechanisms that govern stem cell characteristics is necessary. Here we provide a review of the literature on NSCs in various aspects of cell therapy, with the main focus on the potential of using biomaterials to control NSC characteristics, differentiation, and delivery. We summarize results from studies on the characteristics of endogenous and transplanted NSCs in rodent models of neurological and cancer diseases, and highlight recent advancements in polymer compatibility and applicability in regulating NSC state and fate. We suggest that the development of specially designed polymers, such as hydrogels, is a crucial issue to improve the outcome of stem cell therapy in the central nervous system. 相似文献
26.
《Cell》2022,185(20):3705-3719.e14
27.
Focal articular cartilage damage can eventually lead to the onset of osteoarthritis with degradation around healthy articular cartilage. Currently, there are no drugs available that effectively repair articular cartilage damage. Several surgical techniques exist and are expected to prevent progression to osteoarthritis, but they do not offer a long‐term clinical solution. Recently, regenerative medicine approaches using human pluripotent stem cells (PSCs) have gained attention as new cell sources for therapeutic products. To translate PSCs to clinical application, appropriate cultures that produce large amounts of chondrocytes and hyaline cartilage are needed. So too are assays for the safety and efficacy of the cellular materials in preclinical studies including animal transplantation models. To confirm safety and efficacy, transplantation into the subcutaneous space and articular cartilage defects have been performed in animal models. All but one study we reviewed that transplanted PSC‐derived cellular products into articular cartilage defects found safe and effective recovery. However, for most of those studies, the quality of the PSCs was not verified, and the evaluations were done with small animals over short observation periods. Large animals and longer observation times are preferred. We will discuss the recent progress and future direction of the animal transplantation studies for the treatment of focal articular cartilage damages using PSCs. 相似文献
28.
29.
30.
Zheyong Huang Yunli Shen Hongmin Zhu Jianfeng Xu Yanan Song Xinying Hu Zhang Shuning Xiangdong Yang Aijun Sun Juying Qian Junbo Ge 《Experimental Animals》2013,62(3):197-203
Cell delivery via the retrograde coronary route boasts less vessel embolism, myocardial
injury, and arrhythmogenicity when compared with those via antegrade coronary
administration or myocardial injection. However, conventional insertion into the coronary
sinus and consequent bleeding complication prevent its application in small animals. To
overcome the complication of bleeding, we described a modified coronary retroinfusion
technique via the jugular vein route in rats with myocardial infarction (MI). A flexible
wire with a bent end was inserted into the left internal jugular vein and advanced slowly
along the left superior vena cava. Under direct vision, the wire was run into the left
cardiac vein by rotating the wire and changing the position of its tip. A fine tube was
then advanced along the wire to the left cardiac vein. This modified technique showed less
lethal hemorrhage than the conventional technique. Retroinfusion via transjugular catheter
enabled efficient fluid or cell dissemination to the majority areas of the free wall of
the left ventricle, covering the infarcted anterior wall. In conclusion, transjugular
cardiac vein catheterization may make retrocoronary infusion a more safe and practical
route for delivering cell, drug, and gene therapy into the infarcted myocardium of
rats. 相似文献